Isis Pharmaceuticals (ISIS) - FREE Research Report

Wender Joseph H who is Director at Isis Pharmaceuticals sold 10,000 shares at $50.98 on Jan. 24, 2014. Following this transaction, the Director owned 31,135 shares meaning that the stake was reduced by 24.31% with the 10,000-share transaction.

The shares most recently traded at $47.46, down $3.52, or 7.42% since the insider transaction. Historical insider transactions for Isis Pharmaceuticals go as follows:

  • 4-Week # shares sold: 362
  • 12-Week # shares sold: 21,093
  • 24-Week # shares sold: 25,987

The average volume for Isis Pharmaceuticals has been 1.2 million shares per day over the past 30 days. Isis Pharmaceuticals has a market cap of $5.8 billion and is part of the health care sector and drugs industry. Shares are up 21.54% year-to-date as of the close of trading on Friday.

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. Currently there are 4 analysts that rate Isis Pharmaceuticals a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ISIS - FREE

TheStreet Quant Ratings rates Isis Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Isis Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Plug Power Just Suffered Some Serious Damage

Closing Bell: Active Oil Rig Activity Falls; U.S. Stocks Retreat From Records

Stocks Lower as GE Depresses Dow, Microsoft Dips

Plug Power Stock Surges on Expanded Walmart Deal